

CURRICULUM VITAE

**TANJA MILOSAVLJEVIC, MSc, PhD**

## Current Title:

Clinical Trials Coordinator Instructor of Research

## Business Address:

LSU Health New Orleans

School of Medicine, Dept. of Surgery CALS, 2021 Perdido St, New Orleans LA 70112, USA

## Business Telephone and Fax:

504.568.6876 (p), 504.568.2202 (f)

## Business email Address:

[tmilos@lsuhsc.edu](mailto:tmilos@lsuhsc.edu)

## Education:

**Undergraduate:**

## Bachelor of Science, Molecular Biology and Physiology

University of Belgrade Belgrade, Republic of Serbia (10/1989 – 08/1993)

## Graduate:

## Master of Science, Molecular Biology

University of Belgrade Belgrade, Republic of Serbia (10/1993 – 04/1996)

**PhD, Molecular Biology** University of Belgrade Belgrade, Republic of Serbia (06/1996 – 12/2000)

## Post-Doctoral Fellowships:

**HEC-EGIDE/ Eiffel Scholarship for post-doctoral studies**

Institute for Human Genetics (IGH)

Montpellier, France (08/2001 – 08/2002)

## Postdoctoral Fellow

Louisiana State University Health New Orleans (LSUHNO), LA, US

Dept. of Pharmacology and Exp. Therapeutics (06/2004 – 12/2006)

## Other:

**Serbian Ministry for Science and Technology Master of Science Fellowship**

Institute for Biological Research “Sinisa Stankovic” (IBISS), Belgrade, Republic of Serbia

(01/1994 – 04/1996)

## Career Development Courses:

1. Cancer Epigenetics: Environmental Influences and Molecular Mechanisms (2015)
2. National Carcinoid & NET Patient Conference (2014, 2016, 2018)
3. NIH Regional workshop on program funding and grant administration (2017)
4. NANETS New Orleans Regional Neuroendocrine Tumor (NET) Education: The Multidisciplinary Management of NET Cancers (2018)
5. The Socratic Method (2018)
6. Becoming a Successful Leader (Inclusive Leadership Training, edX, 2019)
7. Louisiana Clinical & Translational Science Center Research Coordinator Program (Levels I-III, 2023)
8. WIRB-Copernicus Group (WCG) online courses (2023)

## Academic, Professional, and Research Appointments:

1. **Research Scientist**

Dept. of Molecular Biology and Biochemistry, Institute for Biological Research “Sinisa Stankovic” (IBISS), Republic of Serbia

(12/2000 – 08/2001)

## Postdoctoral Fellow

Dept. Of Cell Cycle and Myogenesis, IGH, Montpellier, France

(09/2001- 08/2002)

## Research Scientist

Dept. of Molecular Biology and Biochemistry, IBISS, Belgrade, Republic of Serbia

(09/2002 – 05/2004)

## Postdoctoral Fellow

Dept. of Pharmacology and Exp. Therapeutics, LSUHNO, LA, US (06/2004 – 12/2006)

## Postdoctoral Researcher

Dept. of Biochemistry and Molecular Biology, LSUHNO, LA, US (01/2007 – 08/2008)

1. **Senior Postdoctoral Researcher** Dept. of Surgery, LSUHNO, LA, US (09/2008 – 11/2015)

## Instructor of Research

Dept. of Surgery, LSUHNO, LA, US (12/2015 - present)

## Clinical Trials Coordinator

Dept. of Surgery, LSUHNO, LA, US (07/2021 - present)

# TEACHING EXPERIENCE AND RESPONSIBILITIES

## Undergraduate, Medical, or Graduate Students trained in molecular biology/ biochemistry techniques:

* + **Undergraduate**: Peter Casey, Steven Lipani, Adrienne Reeks, Sheradie Jackson, Amira Karagic, Ariana Dirige, Clarke Allen, Pearl Watson, Alana Williams, Joel Epling, Jaclyn Mehrez, Bailey Gentile
  + **Post-baccalaureate**: Elise Juge.
  + **Medical students**: Zacchary Keats, Russ Guidry
  + **Surgical residents**: Michael Hall, Jennifer Owen

# RESEARCH AND SCHOLARSHIP

**Grants and Contracts:**

1. **Grant: “***Combinatorial signaling through MEK1” Sponso*r: NIH (2004-2006)

*Role*: postdoctoral fellow

* + Project growth relied on daily collaboration with multidisciplinary scientists within LSU Cell Adhesion and Migration Group and mastering a wide range of techniques for studying gene expression and protein-protein interactions

1. **Grant: “***The mechanisms of action of Nischarin in tumor cell migration and invasion”* *Sponsor*: NIH (2007-2008)

*Role*: postdoctoral researcher

* + Completed experiments and contributed to manuscript preparation
  + Data published in one manuscript and presented in two poster presentations

1. **Pilot Grant:** “*Modulation of angiogenic gene expression by black raspberry (BR) extract”*

*Sponsor:* Pennington Biomedical Research Center *(*2011-2012) *Role*: senior postdoctoral researcher

* + Identified candidate BR-response genes in human vein, data interpretation and presentation (interim and final project reports)
  + Data presented at two meetings (local and national)

1. **Angiogenic Switch Project**: "*Define molecular signature responsible for angiogenic switch"*

Sponsor: LSUHNO Foundation (2009-2021)

*Role:* Co-Investigator/ PI

* + Developed a protocol for harvesting neovessels from patient-derived tissues (vessels and neuroendocrine tumors) for genetic/ protein characterization in patented Human Vein/ Tumor Angiogenesis Assay
  + Defined the molecular signature responsible for angiogenic switch
  + Data presented at two local meetings

1. **Human Neuroendocrine Tumors (NETs) project**

Sponsor: LSU Health Foundation New Orleans/ private donors: (2009-2021)

*Role*: Co-investigator

* + Liaison clinical laboratory staff with Neuroendocrine Cancer experts and oversaw banking of tumor specimens and equipment acquisition for the only exclusively Neuroendocrine Tumor Bank (~1,400 specimens/ ~1200 patients) in US
  + Coordinated laboratory testing of various compounds (pharmacological compounds and botanicals) and their effect on blood vessel growth in human NETs. Test results aided in therapy selection for NET patients with metastatic disease (personalized cancer patient care)
  + Conducted on-site training of personnel, provided in-service education as needed, and ensured compliance with all applicable certification standards and regulations
  + Data presented at eighteen meetings and five published abstracts

1. **Grant**: "*Development of Shared NET PDX Repository" Sponso*r: NET DRP SPORE (2016-2017)

*Role*: Co-investigator

* + Managed Neuroendocrine Tumor Bank and specimen sharing with collaborators
  + Cooperated with Neuroendocrine Group (University of Iowa) to develop NET PDX from cryopreserved NET specimens

1. **LSU “Leverage Innovation for Technology Transfer (LIFT2) Fund:** "*Validation of Screening Modality to Diagnose Neuroendocrine Tumors (NETs) of the Gut*" Sponsor: LSUHNO (2017-2020)

*Role*: Co-investigator

* + Aim: Design and development of innovative diagnostic test for rapid at-home and Point-of-Care early detection of rare neuroendocrine tumors
  + Investigated the methylation profile of small bowel NETs and whether this pattern can be used to identify patients with this type of tumor

1. **Biomarker Discovery project:** “*Robert & Kay Watson Biomarker Discovery & Treatment Research*”

Sponsor: LSUHNO Foundation (2018-2021)

*Role*: Co-investigator

* + Whole-exome (Tempus xE panel, DNA) and full transcriptome (RNA) sequencing of NETs with the goal of better understanding the molecular composition of NET patients and how their genomic profile relates to therapy, response and outcomes
  + Tumor specimen banking and processing for sequencing

1. **Clinical Trials** (2021-now)

Supported all clinical trial related activities in a critical, fast-paced, and high visibility clinical program. Prepared and organized regulatory study documentation.

1. **Trial:** “*A Prospective, Double-Blinded, Randomized Controlled Trial of Dehydrated Human Amniotic-Chorionic Membrane for Incisional Hernia Prophylaxis*” –

Sponsor: LSUHNO (2021-now)

*Role*: Clinical Trial Coordinator

* + Collaborated with diverse clinical research team and coordinated daily clinical trial activities
  + Subject eligibility assessment, enrollment and follow-up, provided appropriate training and tools for study team members, built lines of communication to manage an ongoing project at all performance sites, data capture in EDC software
  + Maintained the trial master file and all study-specific source documentation in accordance with University compliance policies and procedures

1. **Trial:** “A Multicenter Registry Study of Avance Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair (RANGER)”

Sponsor: AXOGEN (2021-2022)

*Role*: Clinical Trial Coordinator

* + Maintained regulatory study documentation, routine site monitoring visits, and site closure procedure documentation in accordance with site and sponsor compliance requirements

1. **Trial:** “Restrata in the Management of Acute Wounds Following Excision of Hidradenitis Suppurativa Lesions”

Sponsor: Unfunded (2022-now)

*Role*: Research Coordinator

* + Maintained regulatory study documentation in accordance with University compliance policies and procedures

1. **Trial:** “Solius UV Light to Improve Serum Vitamin D Levels in Vitamin D Deficient Adults

Sponsor: SOLIUS (2022-now)

*Rol*e: Research Coordinator

* + Maintained study-related documentation in accordance with site and sponsor compliance requirements
  + Collaborated with clinical research team and coordinated daily clinical trial activities

1. **Clinical Research Studies** (2009-now)

Prepared and maintained regulatory study documentation for clinical research studies.

1. “A study of human tumor angiogenesis using a fibrin-thrombin clot model” (PI: Dr. Woltering)
2. “Inhibition of angiogenesis using the human placental vein model” (PI: Dr Milosavljevic)
3. “Organotypic culture of human tissue” (PI: Dr Lau)
4. “Developing novel three-dimensional model systems for investigating liposarcoma microenvironment in tumor development” (PI: Dr Lau)
5. “Limb Salvage through Tissue Engineering: A Novel Treatment Modality using Dehydrated Human Amnion/Chorion Membrane” (PI: Dr Lau)
6. “Cutis Graft for Hernia Repair” (PI: Dr Hodgdon)
7. “Efficacy of Short Chain Fatty Acid Infusion on Human Xenograft Tumor Model” (PI: Dr Hodgdon)
8. “Suture Training” (PI: Dr. Morrison)

## Funded applications

1. **LSU “Leverage Innovation for Technology Transfer (LIFT2) Fund:** *“Development of novel screening method for neuroendocrine tumors of the gut*” (2019-2021)

*Role*: Co-investigator

- Development of a non-invasive screening tool for an early detection of small bowel NETs

## Journal Publications:

**Refereed**

* 1. Grigorov I, Bogojevic D, **Milosavljevic T**, Sekularac S, Petrovic M. Characterization of P 29 involved in the regulation of haptoglobin gene expression in rat liver during acute phase response. Jugoslav Med Biohemija-Yugoslav Med Biochem. 1996; 15 (4):311-312.
  2. Sekularac S, Grigorov I, Petrovic M, Bogojevic D, **Milosavljevic T**, Sevaljevic L. Regulation of transcription of rat haptoglobin gene in acute inflammation - characterization of carbohydrate moiety of transcription factor P70. Jugoslav Med Biohemija-Yugoslav Med Biochem. 1996; 15 (4):308-308.
  3. Petrovic M, Grigorov I, **Milosavljevic T**, Sekularac S, Bogojevic D. The role of rat liver nucleoproteins in transcriptional regulation of rat haptoglobin and alpha (2)- macroglobulin genes during the acute-phase reaction. Jugoslav Med Biohemija- Yugoslav Med Biochem. 1996; 15 (4):311-311.
  4. Petrovic M, Grigorov I, Milosavljevic T, Bogojevic D, Sekularac S, Sevaljevic L. Structural and functional homology between the 29 kD rat liver nucleoprotein and the high mobility group 1 protein. Mol Biol Rep. 1996; 23 (2):79-85. doi: 10.1007/BF00424433.
  5. Petrovic M, Grigorov I, **Milosavljevic T**, Bogojevic D. The DNA binding affinity of rat liver nucleoproteins to the alpha (1)-acid glycoprotein gene. Biochem Mol Biol Int. 1996; 40 (4):741-749.
  6. **Milosavljevic T**, Grigorov I, Bogojevic D, Sekularac S, Petrovic M. The acute phase-dependant increase in binding affinity of rat liver nucleoproteins to the hormone regulatory element of haptoglobin gene. Jugoslav Med Biohemija- Yugoslav Med Biochem. 1996; 15 (4):310-310.
  7. Bogojevic D, Grigorov I, Sekularac S, **Milosavljevic T**, Petrovic M. Acute phase- related changes in binding affinity of foetal liver nucleoproteins to regulatory elements of alpha(2)-macroglobulin, alpha(1)-acid glycoprotein and haptoglobin gene. Jugoslav Med Biohemija-Yugoslav Med Biochem. 1996; 15(4):309-309.
  8. Grigorov I, **Milosavljevic T**, Petrovic M. Acute-phase induced phosphorylation of rat liver nucleoprotein p70 modulates its binding affinity for the haptoglobin gene. Biochem Mol Biol Int. 1998; 45(5):1067-1072.
  9. Grigorov I, **Milosavljevic T**, Cvetkovic I, Petrovic M. Participation of two isoforms of C/EBP beta transcription factor in the acute-phase regulation of the rat haptoglobin gene. Cell Biol Int. 1998; 22(9-10):685-693. doi: 10.1006/cbir.1998.0307.
  10. Grigorov I, Lazic T, Cvetkovic I, **Milosavljevic T**, Petrovic M. STAT3 involvement in the acute phase-related expression of the rat haptoglobin gene. Mol Biol Rep. 2000; 27(2):81-86. doi: 10.1023/A:1007177605135.
  11. Grigorov I, **Milosavljevic T**, Cvetkovic I, Petrovic M. HMG-1 as regulatory trans- acting protein in the acute phase-induced expression of the rat liver haptoglobin gene. Gen Physiol Biophys. 2001; 20(4):401-412.
  12. Grigorov I, Lazic T, Cvetkovic I, **Milosavljevic T**, Petrovic M. Opposite nuclear level and binding activity of STAT5B and STAT3 proteins with rat haptoglobin gene under normal and turpentine induced acute phase conditions. Mol Biol Rep. 2001; 28(4):217-222. doi: 10.1023/A:1015749109119.
  13. **Milosavljevic TS**, Petrovic MV, Cvetkovic ID, Grigorov II. DNA binding activity of C/EBP beta and C/EBP delta for the rat alpha (2)-macroglobulin gene promoter is regulated in an acute-phase dependent manner. Biochemistry (Moscow); 67(8):918-26.
  14. **Milosavljevic T**, Lazic T, Uskokovic A, Petrovic M, Grigorov I. Expression of the rat liver haptoglobin gene is mediated by isoforms of C/EBP alpha, -beta and -delta proteins. Gen Physiol Biophys. 2003; 22(2):181-190.
  15. Grigorov I, **Milosavljevic T**, Ilic M, et al. The effect of chronic food restriction on liver acute phase protein response in female and male wistar rats. Acta Vet -Beogr. 2004; 54(1):13-20. doi: 10.2298/AVB0401013G.
  16. Grigorov I, Cvetkovic I, **Milosavljevic T**, et al. The effect of O-GlcNAc glycosylation of rat liver nucleoproteins on their acute phase-dependent binding ability to the hormone responsive element of the haptoglobin gene. Gen Physiol Biophys. 2004; 23(3):367-374.
  17. Ding Y, **Milosavljevic T**, Alahari SK. Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion. Mol Cell Biol. 2008; 28(11):3742-3756. doi: 10.1128/MCB.01832-07.

## Published Abstracts:

1. Hall M, **Milosavljevic T**, Casey P, Anthony CT, Woltering EA. Somatostatin receptor subtypes 1-5 gene expression differs in multiple sites in the same individual. Ann Surg Oncol. 2012;19:S53-S53.
2. **Milosavljevic T**, Guidry RM Jr, Juge EN, Woltering EA. The effect of Erlotinib treatment on human angiogenesis*.* Cancer Research 76(14) Tumor biology:3279- 3279, Abstract 3279, July 2016 (2016). doi: 10.1158/1538-7445.AM2016-3279.
3. Juge EN, **Milosavljevic T**, Casey P, Hall M, Woltering EA. The effect of Dovitinib on angiogenesis in human neuroendocrine tumors. Cancer Research 77(15) Endocrinology:1799-1799, Abstract 1799, July (2016). doi: 10.1158/1538- 7445.AM2016-1799.
4. **Milosavljevic T**, Chouest EJ, Anthony CE, Dirige A, Wang YZ, Boudreaux JP, Ramcharan T, Woltering EA. *In vitro* screening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors Cancer Research 77(13), Tumor biology:780-780, Abstract 780, July (2017). doi: 10.1158/1538-7445.AM2017-780.
5. Kaemmer C, Howe J, Galbraith J, Galbraith J, Knudson C, Darbro B, **Milosavljevic T**, Woltering E, Wen K-K, Wu M, Quelle D. Developing model systems of neuroendocrine tumors: Cell lines and patient-derived xenograft (PDX) tumors.&nbsp; Pancreas. 2018; 47(3):343.

## Scientific Presentations:

### Local Posters

1. **Milosavljevic T**, Walch A, Baranwal S, Alahari SK. The integrin-binding protein Nischarin interacts with tumor suppressor LKB1 in breast cancer. Graduate School Research Day, LSU Health Sciences Center, New Orleans, LA, US (2008).
2. Lipani S, **Milosavljevic T**, Woltering EA. Valproic acid’s effect on Notch gene expression in neuroendocrine tumors of the liver. Short-term Research experiences in Cancer. Stanley Scott Cancer Center-LSUHSC, New Orleans, LA and NCI, US (2012).
3. Casey PM, **Milosavljevic T**, Woltering EA. The effect of dovitinib on human angiogenesis. Short-term Research experiences in Cancer. Stanley Scott Cancer Center-LSUHSC, New Orleans, LA and NCI, US (2012).
4. **Milosavljevic T**, Anthony, CT, Casey PM, Juge EN, Zabaleta, J, Woltering EA. Black Raspberry Extract Modulates Angiogenic Gene Expression. Louisiana Cancer Research Consortium Retreat 2014; New Orleans, LA, US (2014).
5. Juge EN, **Milosavljevic T**, Reeks AM, Owens JA, Woltering EA. Regorafenib (Stivarga) Effectively Inhibits Angiogenesis in Neuroendocrine Tumors. Louisiana Cancer Research Consortium Retreat 2014; New Orleans, LA, US (2014).
6. Guidry, R, Juge EN, **Milosavljevic T**, Woltering, EA. The effect of Erlotinib on Human Angiogenesis. Short-term Research experiences in Cancer. Stanley Scott Cancer Center-LSUHSC, New Orleans, LA and NCI, US (2015).
7. Juge EN, **Milosavljevic T**, Boudreaux JP, Wang YZ, Woltering EA. Dovitinib Effectively Inhibits Angiogenesis in Neuroendocrine Tumors, Louisiana Cancer Research Consortium Retreat 2015; New Orleans, LA, US (2015).
8. **Milosavljevic T**, Juge EN, Zabaleta, J, Hall MA, Boudreaux, JP, Wang, YZ, Woltering EA. Angiogenic Gene Expression in Primary Neuroendocrine Tumors and Their Metastases. Louisiana Cancer Research Consortium Retreat 2015; New Orleans, LA, US (2015).
9. **Milosavljevic T**, Chouest EJ, Zabaleta J, Anthony CE, Woltering EA. Two novel model systems for studying the angiogenic switch *in vitro*. 4th Annual LA Conference on Computational Biology & Bioinformatics, New Orleans, LA, US (2016).
10. **Milosavljevic T**, Chouest EJ, Zabaleta J, Anthony CE, Woltering EA. The novel human vein model systems for studying the angiogenic switch *in vitro*. Louisiana Cancer Research Consortium Retreat 2016, New Orleans, LA, US (2016).
11. **Milosavljevic T**, Chouest EJ, Anthony CE, Dirige A, Wang YZ, Boudreaux JP, Ramcharan T, Woltering EA. *In vitro* screening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors. Louisiana Cancer Research Consortium Retreat 2017, New Orleans, LA, US (2017).
12. **Milosavljevic T**, Hall M, Del Valle, L, Juge EN, Zabaleta, J, Boudreaux, JP, Wang YZ, Anthony CT, Woltering EA. Angiogenic gene expression in primary and metastatic neuroendocrine tumors. 5th Annual LA Conference on Computational Biology & Bioinformatics, New Orleans, LA, US (2017).
13. **Milosavljevic T**, Allen CM, Chouest E, Woltering EA. The effect of natural compounds on angiogenesis in human inferior vena cava. Louisiana Cancer Research Consortium Retreat 2017, New Orleans, LA, US (2018).
14. **Milosavljevic T**, Chouest EJ, Zabaleta J, Woltering EA. Gene expression analysis of physiologic angiogenesis over time. Louisiana Cancer Research Consortium Retreat, Molecular Signaling, New Orleans, LA, US (2019).
15. Gentile B, **Milosavljevic T**, Chouest E, Gabra M, Mamikunian P, Eugene A. Woltering. Development of early-detection test for neuroendocrine tumor in stool. Louisiana Cancer Research Consortium Retreat, Clinical and Translational Research, New Orleans, LA, US (2020).
16. Mehrez J, Gentile B, **Milosavljevic T**, Chouest E, Eugene A. Woltering. In vitro model system for intact, human cancer analysis of phenotypic angiogenesis and gene expression. Louisiana Cancer Research Consortium Retreat, Cancer Genetics, New Orleans, LA, US (2020).
17. Maier MA, **Milosavljevic T**, Lau FHP. The New Orleans Hernia Event Reduction, a Novel Indication for Amnion (NO HERNIA) Trial. LSUHSC Annual Research Fair, New Orleans, LA (10/18/2021).
18. Maier MA, **Milosavljevic T**, Lau FHP. The New Orleans Hernia Event Reduction, a Novel Indication for Amnion (NO HERNIA) Trial, Our Lady of the Lake, Louisiana State University, Quality. Research Day, Baton Rouge, LA (2022)
19. Messa GE, Maier, MA, **Milosavljevic T**, Lau FHP. The New Orleans Hernia Event Reduction, a Novel Indication for Amnion (NO HERNIA) Trial. LSUHSC Annual Research Fair, New Orleans, LA (2022)

### National Posters

1. Wang YF, Lavezzi TS, **Milosavljevic T**, Walch AN, Baranwal S, Alahari SK. MicroRNA Profiling of Human Breast Cancer Cell Line MDA-MB-231 (sub line 4175) and MCF10A. 47th Annual American Society for Cell Biology meeting. Washington, DC, US (2007).
2. Hall MA, **Milosavljevic T**, Casey P, Anthony CT, Woltering EA. Somatostatin Receptor Subtypes 1-5 Gene Expression Differs in Multiple Sites In the Same Individual. Society of Surgical Oncology, 65th Annual Cancer Symposium. Orlando, FL, US (2012).
3. Hall MA, **Milosavljevic T**, Casey P, Juge E, Anthony CT, Wood KC, Woltering EA. Anti-angiogenic effect of Dovitinib in Neuroendocrine Tumors over-expressing the FGFR3 gene. American College of Surgeons 2013 Clinical Congress, Washington DC, US (2013).
4. **Milosavljevic T**, Anthony CT, Casey PM, Juge EN and Woltering EA. Modulation of angiogenic gene expression by Black Raspberry extract. American Institute of Cancer research, Annual research Conference. Food, Nutrition, Physical activity and cancer, Bethesda, MD, US (2013).
5. **Milosavljevic T**, Hall M, Del Valle, L, Juge EN, Zabaleta, J, Boudreaux, JP, Wang, YZ, Catherine T. Anthony, Woltering EA. Angiogenic gene expression in primary neuroendocrine tumors and their metastases. American Society of Clinical Oncology Annual Meeting, San Francisco, CA, US (2016).
6. **Milosavljevic T**, Juge EN, Reeks AM, Owens JO, Wang YZ, Boudreaux JP, Woltering EA. Effect of Regorafenib on Angiogenesis in Neuroendocrine Tumors *in vitro*. American Society of Clinical Oncology Annual Meeting, San Francisco, CA, US (2016).
7. **Milosavljevic T**, Guidry RM Jr, Juge EN, Woltering EA. The effect of Erlotinib treatment on human angiogenesis*.* American Association of Cancer Research Annual Meeting, New Orleans, LA, US (2016).
8. Juge EN, **Milosavljevic T**, Casey P, Hall M, Woltering EA. The effect of Dovitinib on angiogenesis in human neuroendocrine tumors. American Association of Cancer Research Annual Meeting, New Orleans, LA, US (2016).
9. Beyer DT, Chouest EJ, **Milosavljevic T**, Wang YZ, Thiagarajan R, Ramirez RA, Campeau RJ, Boudreaux JP, Ricks MJ, Woltering EA. In-Vitro Evaluation of Angiogenesis Does Not Correlate with the Survival of Neuroendocrine Tumors. American College of Surgeons Clinical Congress, Washington DC, US (2016).
10. **Milosavljevic T**, Chouest EJ, Anthony CE, Dirige A, Wang YZ, Boudreaux JP, Ramcharan T, Woltering EA. *In vitro* screening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors American Association of Cancer Research Annual Meeting, Washington, DC, US (2017).
11. Chouest E, **Milosavljevic T**, Zabaleta J, Woltering E. Gene Expression Regulation of Human Physiologic Angiogenesis Over Time Angiogenesis, Gordon Research Seminar: Molecular and Cellular Dynamics of Endothelial Cells in Health and Disease (Conferee ID: 1419074), Newport, RI, US (2019). *Awarded presentation*
12. Skill N, Campbell E, **Milosavljevic T**, Chouest E, Voros E, Woltering E, Maluccio

M. Liquid biopsy metabolomic profiling of Neuroendocrine cancer patients. 12th

Annual North American Neuroendocrine Tumor Society Symposium (B-20), Boston, MA, US (2019).

1. Mehrez J, Gentile B, Skill N, **Milosavljevic T**, Chouest E, Maluccio MA, Woltering

E. Mapping anti-angiogenic proteome associated with black raspberry and gallic acid treatment in neuroendocrine cancer. 13th Annual North American Neuroendocrine Tumor Society Virtual Symposium (2020).

1. Messa GE, Maier, MA, **Milosavljevic T**, Lau FHP. The New Orleans Hernia Event Reduction, a Novel Indication for Amnion (NO HERNIA) Trial. American College of surgeons 2023, SF317 | General Surgery VIII.

### International Posters

1. Hall MA, **Milosavljevic T**, Casey P, Anthony, CT, Woltering EA. Somatostatin Receptor Subtypes 1-5 Gene Expression Differs in Multiple Sites From the Same Individual. The 14th International symposium on Anti-Angiogenic therapy. La Jolla, California, US (2012).
2. Kaemmer C, Howe J, Galbraith J, Knudson C, Darbro B, **Milosavljevic T**, Woltering E, Wen K-K, Wu M, Quelle D. Developing Model Systems of Neuroendocrine Tumors: Cell Lines and Patient-Derived Xenograft (PDX) Tumors 10th Annual North American Neuroendocrine Tumor Society Symposium, Philadelphia, PA, US (2017).

# SERVICE ACTIVITIES

### Special assignments – ad hoc task forces/working groups, projects, etc.:

1. *Judged presentations* at AACR Undergraduate Student Caucus & Poster Competition - 11th and 12th Annual AACR Meeting (New Orleans, LA, US, 2016; Washington DC, VA, US, 2017)
2. *Mentored students* at “The conquest of cancer and the next generation of cancer researchers” AACR program about education and research - 11th and 12th Annual AACR Meeting (New Orleans, LA, US, 2016; Washington DC, VA, US, 2017)

### Community Service Activities:

* + Volunteered in non-profit Young Leadership Council community project to reactivate youth training programs in the Central City neighborhood of New Orleans in the aftermath of Hurricane Katrina (2006)